Temozolomide + O6-benzylguanine

Temozolomide + O6-benzylguanine is a combination therapy investigated primarily for the treatment of malignant gliomas, including glioblastoma multiforme and anaplastic glioma. Temozolomide is an oral alkylating agent that induces cytotoxicity by methylating DNA at the O6 position of guanine, leading to tumor cell death. However, resistance to temozolomide often develops due to the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT), which removes these methyl groups and repairs the damage. O6-benzylguanine acts as a pseudosubstrate inhibitor of MGMT by transferring its benzyl group to MGMT's active site, thereby inactivating it and depleting its activity in tumor cells. This depletion sensitizes tumors to temozolomide by preventing repair of cytotoxic lesions, potentially overcoming resistance mechanisms[1][2][5][8]. The combination has been evaluated in both adult and pediatric populations with recurrent or progressive high-grade gliomas; clinical trials have shown that while this strategy can restore some sensitivity in certain subtypes (notably anaplastic glioma), results are mixed for others such as glioblastoma multiforme[1][2][8].

Other names

TMZO6BGO-6BGO 6BGO6-BGO-6-BGO 6-BG